Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tejnaksh Healthcare's annualized ROCE % for the quarter that ended in Mar. 2026 was 4.81%.
Tejnaksh Healthcare (BOM:539428) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Tejnaksh Healthcare ROCE % Related Terms
Tejnaksh Healthcare ROCE % Historical Data
* Premium members only.
The historical data trend for Tejnaksh Healthcare's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tejnaksh Healthcare (BOM:539428) has a ROCE % of 4.81% as of Mar. 2026.
Is Tejnaksh Healthcare's ROCE % too high?
Tejnaksh Healthcare's current ROCE % is 4.81%. The Healthcare Providers & Services industry median ROCE % is 6.41. Tejnaksh Healthcare's value of 4.81% is 25% below this industry median. Overall, Tejnaksh Healthcare has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tejnaksh Healthcare's ROCE % compare to HCA and THC?
Tejnaksh Healthcare's ROCE % of 4.81% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Tejnaksh Healthcare's value of 4.81% is 25% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 641 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tejnaksh Healthcare's current ROCE % of 4.81% is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tejnaksh Healthcare's current ROCE % is 4.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tejnaksh Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Tejnaksh Healthcare (BOM:539428) is currently considered Possible Value Trap. The stock's GF Value™ is ₹20.94, compared to a current price of ₹13.72 — trading 34.5% below its estimated fair value. The current ROCE % is 4.81% and 25% below the Healthcare Providers & Services industry median of 6.41. Tejnaksh Healthcare's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Tejnaksh Healthcare (BOM:539428), the current ROCE % is 4.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tejnaksh Healthcare (BOM:539428) Overvalued in 2026?
Based on GuruFocus' analysis, Tejnaksh Healthcare stock appears to be undervalued.
The current stock price of ₹13.72 is trading 34.5% below its estimated GF Value™ of ₹20.94.
GuruFocus considers Tejnaksh Healthcare to be Possible Value Trap.
Key valuation signals for BOM:539428:
ROCE %: 4.81%
GF Value™: ₹20.94 vs. price of ₹13.72 (34.5% below fair value)
Industry Position: 25% below the Healthcare Providers & Services median
No single metric tells the full story. See the BOM:539428 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tejnaksh Healthcare Ltd is engaged in the provision of hospital and healthcare services. Geographically, it operates only in India. The company has a single operating segment, namely health care services. The company domains include Urology Hospitals; Nephrology Hospitals; Dental Clinics; Healthcare Equipment, Research and Development and others. It generates maximum revenue from fees charged under contract for inpatient and outpatient hospital services and also includes sale of medical and non-medical items. Hospital services include charges for accommodation, medical professional services, pathology and pharmaceutical goods used in treatments given to patient.
72GF Score
Get the complete analysis for BOM:539428
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539428 has been successfully added to your 
